Business Wire

NJ-OPEX

8.6.2022 09:02:06 CEST | Business Wire | Press release

Share
OPEX® Introduces Right-Speed™ Scanning Technology to Information Management Experts in Europe

OPEX® Corporation, a global leader in Next Generation Automation for almost 50 years, is introducing leading-edge Document and Mail Automation technology on 22 June 2022 to attendees of the Association for Intelligent Information Management (AIIM) Forum Europe in London.

OPEX’s new Gemini™ high-volume scanner is “Right-Speed™,” an unrivaled scanning capability that enables different types of documents to be scanned at different speeds without changing equipment to maximize throughput and operational efficiency.

“Gemini scans the widest range of document types, sizes and conditions—and handles them at the right speed for the job,” said Scott Maurer, President, OPEX International. “Whether documents need to be scanned at high speed, packet speed or drop feed, Gemini is the most versatile scanner available.”

With scan speeds of up to 240 pages per minute, the Gemini scanner features a dual-feeder design and the ability for continuous feeding. Its five programmable sort bins enable unique sorting capabilities and easy document handling. Other features include software configurability, scalability for the future, best-in-class service, and an ergonomic, customizable work area designed to enhance operator comfort and productivity.

Ideal for service bureaus, BPOs, government institutions, tax entities, medical records companies, insurance agencies, law firms, and a host of other industries, the Gemini scanner with “Right-Speed” technology was first unveiled in April in the U.S. during the 2022 AIIM Conference in Denver, Colorado.

“We are excited to showcase the Gemini scanner and ‘Right-Speed’ technology to customers across Europe who are looking for document automation solutions to solve their most pressing business challenges,” said Maurer. “We have been expanding our facilities, personnel and infrastructure to meet the growing automation needs of customers in Europe and around the world.”

An AIIM Forum Europe Partner, OPEX will be the only company demonstrating equipment live at the event.

In the coming months, OPEX will be able to demonstrate the Gemini scanner and “Right-Speed” technology at company facilities in Germany, France and the U.K. Customers who do not wish to travel in person can attend private webinars to learn about the Gemini scanner and the rest of OPEX’s existing Document and Mail Automation portfolio, which includes the Falcon® Series of high-volume, one-touch scanners that eliminate or significantly reduce prep time.

With generations of industry expertise, a proven track record developing first-class automation capabilities and advanced engineering, and a heritage of excellence, OPEX continuously reimagines automation technology to help clients solve their most significant business challenges today and in the future. For nearly five decades, OPEX has served as a trusted partner, collaborating closely with clients to develop customized, scalable solutions.

OPEX is vertically integrated—innovating, engineering, manufacturing, selling, and servicing all its automated solutions. This translates to the highest degree of quality equipment, reliable operations, product longevity, and an exceptional client experience.

To learn more, please visit OPEX.com .

About OPEX
OPEX Corporation is a global leader in Next Generation Automation, providing innovative, unique solutions for warehouse, document and mail automation. With headquarters in Moorestown, NJ, USA—and facilities in Pennsauken, NJ; Plano, TX; France; Germany; Switzerland; the United Kingdom; and Australia—OPEX has more than 1,500 employees who are continuously reimagining and delivering customized, scalable technology solutions that solve the business challenges of today and in the future.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release

- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating

Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release

Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built

DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release

DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict

Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release

Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye